Absci Prices $100M Offering at 26.5% Discount; Eli Lilly Invests $40M
ABSI has more than doubled off its 52-week low of $2.24 on elevated volume (6.9× avg).
Summary
Absci Corp announced the pricing of a $100 million underwritten public offering at a 26.5% discount, with Eli Lilly & Co. investing $40 million alongside other institutional investors.
Key Events · Financing and Capital Events · ABSI
-
Underwritten Public Offering Priced
Absci Corp entered into an underwriting agreement to sell 13,495,277 shares of common stock, expecting gross proceeds of approximately $100 million and net proceeds of $93.5 million.
-
Significant Discounted Pricing
The shares are being sold at an offering price of $7.41 per share, representing a 26.5% discount compared to the current stock price of $10.08.
-
Strategic Investor Participation
The offering includes a $40 million investment from Eli Lilly & Co., along with participation from other leading financial institutions such as Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile.
-
Use of Proceeds for ABS-201 Advancement
Net proceeds will primarily fund the advancement of ABS-201, the company's AI-designed anti-PRLR antibody product candidate, across androgenetic alopecia and endometriosis, and for general corporate purposes.
Analysis · ABSI · Industrial Applications And Services
Absci Corp has priced a significant $100 million underwritten public offering at a substantial discount to its current market price. While the 26.5% discount and resulting dilution are negative for existing shareholders, the offering is bolstered by a $40 million investment from Eli Lilly & Co. and participation from other leading institutional investors. This strategic backing, especially following recent positive Phase 1 data for its lead drug candidate ABS-201, provides crucial funding for the advancement of this key pipeline asset and extends the company's operational runway.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 35.1% of the 1081 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABSI was trading at $10.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.24 to $11.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.